What is HC Wainwright’s Forecast for ESPR FY2026 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a report released on Thursday, November 6th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will earn $0.40 per share for the year, up from their prior estimate of $0.35. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2027 earnings at $0.64 EPS and FY2028 earnings at $0.90 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.07). The firm had revenue of $87.31 million for the quarter, compared to the consensus estimate of $78.33 million.

A number of other brokerages have also commented on ESPR. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Wednesday, October 8th. Wall Street Zen downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Esperion Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Esperion Therapeutics Stock Up 1.8%

ESPR traded up $0.05 during trading on Friday, hitting $2.55. The company had a trading volume of 2,926,019 shares, compared to its average volume of 5,353,384. The firm’s 50-day moving average price is $2.70 and its 200 day moving average price is $1.75. The company has a market capitalization of $513.12 million, a PE ratio of -5.19 and a beta of 0.92. Esperion Therapeutics has a one year low of $0.69 and a one year high of $3.94.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its holdings in shares of Esperion Therapeutics by 7.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 72,705 shares of the biopharmaceutical company’s stock valued at $72,000 after buying an additional 4,979 shares during the last quarter. CWM LLC raised its position in Esperion Therapeutics by 46.5% during the third quarter. CWM LLC now owns 19,674 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 6,249 shares in the last quarter. DHJJ Financial Advisors Ltd. lifted its stake in Esperion Therapeutics by 209.2% in the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 6,380 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Esperion Therapeutics by 54.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 23,916 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 8,394 shares during the last quarter. Finally, Private Advisor Group LLC grew its position in shares of Esperion Therapeutics by 33.2% in the 1st quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 10,000 shares during the period. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.